Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthias P Ebert

Showing results (121-130 of 139) with videos related to

Pageof 14
Sort By:
British Journal of Cancer|May 19, 2026
Differential effects of prior versus concomitant Steroid and Antibiotic Treatment on Immunotherapy Efficacy - A Pooled Analysis of the RAMONA, INTEGA, OPTIM, ELDORANDO, FORCE, TITAN-RCC and TITAN-TCC Trials of the German AIO Study GroupIsabella C Wiest, Lena Dreikhausen, Ralph Keller, et al.
Annals of Hepatology|October 31, 2025
MRI imaging and machine learning based radiomics for detection of mixed HCC and CCA tumorsYuquan Qian, Qiao-Yuan Lu, Isaac Rodriguez, et al.
The Lancet. Healthy Longevity|September 13, 2022
Second-line therapy with nivolumab plus ipilimumab for older patients with oesophageal squamous cell cancer (RAMONA): a multicentre, open-label phase 2 trialMatthias P Ebert, Nadja M Meindl-Beinker, Tobias Gutting, et al.
Cell Death & Disease|July 12, 2023
Tolerance of repeated toxic injuries of murine livers is associated with steatosis and inflammationSeddik Hammad, Christoph Ogris, Amnah Othman, et al.
Nature Communications|June 6, 2022
The drug-induced phenotypic landscape of colorectal cancer organoidsJohannes Betge, Niklas Rindtorff, Jan Sauer, et al.
NPJ Genomic Medicine|May 29, 2024
Analysis of cell free DNA to predict outcome to bevacizumab therapy in colorectal cancer patientsTom Venken, Ian S Miller, Ingrid Arijs, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 16, 2022
FLOT Versus FLOT/Trastuzumab/Pertuzumab Perioperative Therapy of Human Epidermal Growth Factor Receptor 2-Positive Resectable Esophagogastric Adenocarcinoma: A Randomized Phase II Trial of the AIO EGA Study GroupRalf-Dieter Hofheinz, Kirsten Merx, Georg M Haag, et al.
Digestion|October 19, 2016
Outcome of Colorectal Cancer Patients Treated with Combination Bevacizumab Therapy: A Pooled Retrospective Analysis of Three European Cohorts from the Angiopredict InitiativeJohannes Betge, Ana Barat, Verena Murphy, et al.
Biochemical and Biophysical Research Communications|July 21, 2024
The TGF-β1 target WISP1 is highly expressed in liver cirrhosis and cirrhotic HCC microenvironment and involved in pro- and anti-tumorigenic effectsAnne Dropmann, Sophie Alex, Katharina Schorn, et al.
The American Journal of Pathology|May 13, 2016
Delta-Like Ligand 4 Modulates Liver Damage by Down-Regulating Chemokine ExpressionZhe Shen, Yan Liu, Bedair Dewidar, et al.
Pageof 14

Showing results (121-130 of 139) with videos related to

Sort By:
Pageof 14
British Journal of Cancer|May 19, 2026
Differential effects of prior versus concomitant Steroid and Antibiotic Treatment on Immunotherapy Efficacy - A Pooled Analysis of the RAMONA, INTEGA, OPTIM, ELDORANDO, FORCE, TITAN-RCC and TITAN-TCC Trials of the German AIO Study GroupIsabella C Wiest, Lena Dreikhausen, Ralph Keller, et al.
Annals of Hepatology|October 31, 2025
MRI imaging and machine learning based radiomics for detection of mixed HCC and CCA tumorsYuquan Qian, Qiao-Yuan Lu, Isaac Rodriguez, et al.
The Lancet. Healthy Longevity|September 13, 2022
Second-line therapy with nivolumab plus ipilimumab for older patients with oesophageal squamous cell cancer (RAMONA): a multicentre, open-label phase 2 trialMatthias P Ebert, Nadja M Meindl-Beinker, Tobias Gutting, et al.
Cell Death & Disease|July 12, 2023
Tolerance of repeated toxic injuries of murine livers is associated with steatosis and inflammationSeddik Hammad, Christoph Ogris, Amnah Othman, et al.
Nature Communications|June 6, 2022
The drug-induced phenotypic landscape of colorectal cancer organoidsJohannes Betge, Niklas Rindtorff, Jan Sauer, et al.
NPJ Genomic Medicine|May 29, 2024
Analysis of cell free DNA to predict outcome to bevacizumab therapy in colorectal cancer patientsTom Venken, Ian S Miller, Ingrid Arijs, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 16, 2022
FLOT Versus FLOT/Trastuzumab/Pertuzumab Perioperative Therapy of Human Epidermal Growth Factor Receptor 2-Positive Resectable Esophagogastric Adenocarcinoma: A Randomized Phase II Trial of the AIO EGA Study GroupRalf-Dieter Hofheinz, Kirsten Merx, Georg M Haag, et al.
Digestion|October 19, 2016
Outcome of Colorectal Cancer Patients Treated with Combination Bevacizumab Therapy: A Pooled Retrospective Analysis of Three European Cohorts from the Angiopredict InitiativeJohannes Betge, Ana Barat, Verena Murphy, et al.
Biochemical and Biophysical Research Communications|July 21, 2024
The TGF-β1 target WISP1 is highly expressed in liver cirrhosis and cirrhotic HCC microenvironment and involved in pro- and anti-tumorigenic effectsAnne Dropmann, Sophie Alex, Katharina Schorn, et al.
The American Journal of Pathology|May 13, 2016
Delta-Like Ligand 4 Modulates Liver Damage by Down-Regulating Chemokine ExpressionZhe Shen, Yan Liu, Bedair Dewidar, et al.
Pageof 14